tetano
Editor, Senior Moderator
J Scleroderma Relat Disord
. 2024 Feb;9(1):16-22.
doi: 10.1177/23971983231210340. Epub 2023 Nov 21. Outcomes in systemic sclerosis patients hospitalized with COVID-19: Insight from the National Inpatient Sample
Huzaifa Ahmad Cheema[SUP] 1 [/SUP], Anum Akhlaq[SUP] 2 [/SUP], Biah Mustafa[SUP] 1 [/SUP], Abia Shahid[SUP] 1 [/SUP], Muhammad Ayyan[SUP] 1 [/SUP], Ehizogie Edigin[SUP] 3 [/SUP]
Affiliations
Objective: COVID-19, a respiratory infection caused by the novel coronavirus SARS-CoV-2, can cause varying degrees of illness ranging from mild respiratory illness to severe respiratory failure. Systemic sclerosis is a chronic autoimmune disease, with an increased prevalence of infections as compared to the general population. In this study, we compare the clinical outcomes and resource utilization for COVID-19 hospitalizations in patients with and without systemic sclerosis.
Methods: We used the National Inpatient Sample database, 2020, to study the characteristics, morbidity, mortality, cost, and resource utilization among primary COVID-19 hospitalizations with and without systemic sclerosis.
Results: There were 1,050,040 patients aged ⩾ 18 years with a diagnosis of COVID-19. Of these, 775 (0.07%) patients had a secondary diagnosis of systemic sclerosis. Although there was no statistically significant difference regarding individual outcomes; in-hospital mortality, vasopressor use, cardiac arrest, acute kidney injury, and disposition to facility were numerically higher in hospitalizations with systemic sclerosis. The composite endpoint of major adverse events was higher in the systemic sclerosis cohort (adjusted odds ratio 1.52, 95% confidence interval: 1.06-2.17, p = 0.022).
Conclusion: COVID-19 patients with systemic sclerosis had worse outcomes (i.e. higher composite endpoint of major adverse events) than those without systemic sclerosis. Further studies are needed to establish a better understanding of the relationship between COVID-19 and systemic sclerosis.
Keywords: COVID-19; National Inpatient Sample database; SARS-CoV-2; scleroderma; systemic sclerosis.
. 2024 Feb;9(1):16-22.
doi: 10.1177/23971983231210340. Epub 2023 Nov 21. Outcomes in systemic sclerosis patients hospitalized with COVID-19: Insight from the National Inpatient Sample
Huzaifa Ahmad Cheema[SUP] 1 [/SUP], Anum Akhlaq[SUP] 2 [/SUP], Biah Mustafa[SUP] 1 [/SUP], Abia Shahid[SUP] 1 [/SUP], Muhammad Ayyan[SUP] 1 [/SUP], Ehizogie Edigin[SUP] 3 [/SUP]
Affiliations
- PMID: 38333522
- PMCID: PMC10848934 (available on 2025-02-01)
- DOI: 10.1177/23971983231210340
Objective: COVID-19, a respiratory infection caused by the novel coronavirus SARS-CoV-2, can cause varying degrees of illness ranging from mild respiratory illness to severe respiratory failure. Systemic sclerosis is a chronic autoimmune disease, with an increased prevalence of infections as compared to the general population. In this study, we compare the clinical outcomes and resource utilization for COVID-19 hospitalizations in patients with and without systemic sclerosis.
Methods: We used the National Inpatient Sample database, 2020, to study the characteristics, morbidity, mortality, cost, and resource utilization among primary COVID-19 hospitalizations with and without systemic sclerosis.
Results: There were 1,050,040 patients aged ⩾ 18 years with a diagnosis of COVID-19. Of these, 775 (0.07%) patients had a secondary diagnosis of systemic sclerosis. Although there was no statistically significant difference regarding individual outcomes; in-hospital mortality, vasopressor use, cardiac arrest, acute kidney injury, and disposition to facility were numerically higher in hospitalizations with systemic sclerosis. The composite endpoint of major adverse events was higher in the systemic sclerosis cohort (adjusted odds ratio 1.52, 95% confidence interval: 1.06-2.17, p = 0.022).
Conclusion: COVID-19 patients with systemic sclerosis had worse outcomes (i.e. higher composite endpoint of major adverse events) than those without systemic sclerosis. Further studies are needed to establish a better understanding of the relationship between COVID-19 and systemic sclerosis.
Keywords: COVID-19; National Inpatient Sample database; SARS-CoV-2; scleroderma; systemic sclerosis.